Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
TBC | exagamglogene autotemcel | Transfusion-dependent β-thalassemia | Pending | |||
TBC | exagamglogene autotemcel | Sickle cell disease (SCD) | Pending | |||
N/A | imiquimod | Gynecological cancers | Withdrawn | |||
TBC | fruquintinib | Metastatic colorectal cancer (mCRC) | Pending | |||
Padcev | enfortumab vedotin | Metastatic urothelial cancer | Pending | |||
Venclexta | venetoclax | Chronic lymphocytic leukemia (CLL). | Pending | |||
Mifegymiso | Mifepristone and misoprostol | Medical termination of pregnancy (gestational age up to 49 days) | Withdrawn | |||
Praxbind | Idarucizumab (Drug Plan Submission) | Reversal of dabigatran anticoagulant effects | Withdrawn | |||
Venclexta | Venetoclax | Withdrawn | ||||
Cyramza | Ramucirumab | Cancelled |